Atectura Breezhaler (indacaterol/mometasone furoate) / Merck (MSD), Novartis, Valeo Pharma 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium

Not yet recruiting
3
28
Europe
QMF149, QVM149, Inhalation powder
University Medical Center Groningen, Novartis Pharma AG
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT05562466: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
3
200
Europe, RoW
QMF149, Budesonide
Novartis Pharmaceuticals
Asthma
05/26
06/26
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT05217810: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting
N/A
600
RoW
Atectura inhalation capsule (150/80ug), Atectura inhalation capsule (150/160ug), Atectura inhalation capsule (150/320ug)
Novartis Pharmaceuticals
Asthma
12/26
12/26

Download Options